https://orcid.org/0000-0002-4598-5128
References
- Dormer L , WalkerJ. Plain Language Summary of Publication articles: helping disseminate published scientific articles to patients. Future Oncol.16(25), 1873–1874 (2020).
- Tap W . ENLIVEN study: pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol.16(25), 1875–1878 (2020).
- Tap WD , GelderblomH, PalmeriniEet al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumor (ENLIVEN): a randomized Phase III trial. Lancet394(10197), 478–487 (2019).
- Brandes AA , ArdizzoniA, ArtioliFet al. Fighting cancer in coronavirus disease era: organization of work in medical oncology departments in Emilia Romagna region of Italy. Future Oncol.16(20), 1433–1439 (2020).
- Elkaddoum R , HaddadFG, EidR, KourieHR. Telemedicine for cancer patients during COVID-19 pandemic: between threats and opportunities. Future Oncol.16(18), 1225–1227 (2020).
- Wozniak AM , RallisKS. Incorporating teleoncology practices in the undergraduate medical curriculum. Future Oncol.doi: 10.2217/fon-2020-0798 (2020) ( Epub ahead of print).
- Hochmair MJ , MorabitoA, HaoDet al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol.16(34), 2799–2808 (2020).
- McDonald L , CarrollR, HarishAet al. Suspected cancer symptoms and blood test results in primary care before a diagnosis of lung cancer: a case–control study. Future Oncol.15(33), 3755–3762 (2019).
- Yoshioka H , KatoT, OkamotoIet al. Therapies after first-line afatinib in patients with EGFRm+ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncol.16(4), 49–60 (2020).
- Hochmair MJ , MorabitoA, HaoDet al. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol.14(27), 2861–2874 (2018).
- Hochmair MJ , MorabitoA, HaoDet al. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol.15(25), 2905–2914 (2019).
- Boehringer Ingelheim . Final analysis of the observational GioTag study: sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer. https://www.boehringer-ingelheim.com/press-release/giotag-final-data
- Feinberg B , HalmosB, GucalpR, TangW, MoehringB, HochmairMJ. Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis. Future Oncol.16(22), 1585–1595 (2020).
- Germetaki T , NichollsC, AdamsRAet al. Blood-based RAS mutation testing: concordance with tissue-based RAS testing and mutational changes on progression. Future Oncol.16(28), 2177–2189 (2020).
- Yekedüz E , KarcıoğluAM, UtkanG, ÜrünY. A clinical dilemma amid COVID-19 pandemic: missed or encountered diagnosis of cancer?Future Oncol.16(25), 1879–1881 (2020).
- Pascual T , CejalvoJM, OliveiraMet al. SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer. Future Oncol.16(24), 1801–1813 (2020).
- Recondo G , MezquitaL. Clinical efficacy, predictive biomarkers and response patterns of immunotherapy combinations for patients with cancer. Future Oncol.16(23), 1659–1664 (2020).
- Ferrara R , MatosI. Atypical patterns of response and progression in the era of immunotherapy combinations. Future Oncol.16(23), 1707–1713 (2020).
- John A , QinB, KalariKR, WangL, YuJ. Patient-specific multi-omics models and the application in personalized combination therapy. Future Oncol.16(23), 1737–1750 (2020).
- Vogel A . Targeting FGFR2 in advanced cholangiocarcinoma: an interview with Arndt Vogel. Future Oncol.16(30), 2373–2374 (2020).